

**EISAI TO PRESENT LATEST DATA ON LENVATINIB AND ERIBULIN
AT ESMO CONGRESS 2016**

Eisai Co., Ltd. (Headquarters: Tokyo, Japan) will present a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode

Product	Abstract title and scheduled presentation date and time (local time)
Lenvatinib Abstract No: 1284	The antitumor activity of lenvatinib (LEN) in combination with everolimus (EVE) in human renal cell carcinoma (RCC) xenograft models is dependent on VEGFR and FGFR signaling Poster Presentation October 10 (Mon), 13:00-14:00
Lenvatinib	Understanding real world treatment patterns, healthcare resource utilization (HRU) and costs

Abstract No: 2616